Tandem Diabetes Care, Inc. (TNDM) Stock Price & How to Invest

Tandem Diabetes Care designs, makes, and sells insulin pumps for people with diabetes. Its flagship products are the t:slim X2 pump and the much smaller Tandem Mobi system, both running Control-IQ+ automated insulin delivery software that reads data from a continuous glucose monitor (CGM) and automatically adjusts insulin dosing. The business works on a razor-and-blade model: Tandem earns an up-front sale when a customer adopts a pump, then recurring revenue from the disposable cartridges, infusion sets, and other supplies that customer buys for years afterward. Pumps integrate with third-party CGMs from Dexcom (G6/G7) and Abbott (FreeStyle Libre), which Tandem does not make itself.

The company shipped its first t:slim pump in 2012 and built its lead through software, releasing Control-IQ automation and then Control-IQ+, which was cleared for commercial use in 2025 and expanded to younger patients and additional indications. The Tandem Mobi, the company's smallest pump, has been ramping in the U.S. and internationally, with Android phone control added in the 2025-2026 window. Tandem competes in a crowded automated insulin delivery market against Insulet's tubeless Omnipod 5, Medtronic's MiniMed 780G, Beta Bionics' iLet, and newer entrant Sequel Medtech's twiist, which launched in 2025. It is also navigating a shift toward a pay-as-you-go (PayGo) pharmacy-channel model that creates near-term pricing headwinds.

Competition is the central risk: Insulet's tubeless Omnipod 5 is the fastest-growing system in the market, Medtronic remains a large incumbent, and newer entrants like Beta Bionics' iLet and Sequel's twiist add pressure, all of which can squeeze Tandem's pricing and pump share. GLP-1 weight-loss drugs are a structural unknown that management has acknowledged may have weighed on the broader insulin-therapy market since 2023, though the long-term effect on pump demand is unclear. Tandem still posts GAAP net losses (about $204.7 million in 2025) and must execute its PayGo pharmacy-channel transition without losing customers, while reimbursement decisions and product execution on Mobi and new integrations all carry uncertainty.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Tandem Diabetes Care, Inc.'s investor relations page or your broker.

• FY2025 revenue: ~$1.0 billion worldwide
• Pump shipments: International >40,000 for FY2025; ~29,000 worldwide in Q1 2026
• U.S. installed base: ~324,000 customers (12/31/25)
• Gross margin (non-GAAP): ~54% FY2025; ~58% Q4 2025
• Adjusted EBITDA: -$46.1M FY2025 (-5%); +$32.9M in Q4 2025
• GAAP net loss: ~$204.7 million (FY2025)
• Market cap: ~$1.1-1.3 billion (2026)

Tandem is best read as a growth medtech rather than a mature, profitable company. The model is razor-and-blade: pumps are sold (sometimes at thin margin) to build an installed base, and the recurring supplies that base buys over the following years drive higher-margin revenue. Heavy spending on research, sales, and manufacturing scale is why the company has not been consistently profitable on a GAAP basis even at roughly $1 billion in sales, so investors tend to watch pump shipments, installed-base growth, gross margin, and the path to positive adjusted EBITDA rather than a simple P/E ratio.

There are three common ways to get TNDM exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic basket, so TNDM sits alongside other stocks that express the same thesis.

Walnut takes the basket route. Describe a thesis where TNDM fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

Tandem is a growth medtech story: an insulin-pump maker reaching roughly $1 billion in annual sales while transitioning toward consistent profitability on the back of its installed base and recurring supplies. The stock tends to be volatile and competition-sensitive, swinging on pump shipment trends, new product ramps like Mobi, and worries about Omnipod, Medtronic, and GLP-1 drugs.

Whether TNDM is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is TNDM a buy?, and where the stock could go from here in the TNDM stock forecast.

For income investors, whether TNDM pays a dividend and how the payout looks is covered in does TNDM pay a dividend?